Tarsus Pharma up on positive trial data for Lyme disease prevention drug

Tarsus Pharmaceuticals

22/02/2024 13:47

** Tarsus Pharmaceuticals' shares  TARS.O  up 9.5% at $33
premarket
    ** Co reports positive data from mid-stage trial of
investigational oral therapeutic for prevention of Lyme disease
    ** Lyme disease is a tick-brone disease that results in
rashes, fever and fatigue 
    ** The trial tested the ability of therapeutic TP-05 to kill
ticks attached to subjects with a single treatment compared to
placebo
    ** Both the high and low doses demonstrated a statistically
significant benefit in killing ticks compared to placebo - Co
    ** Up to last close, stock marginally down YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))